Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of subcutaneous isatuximab with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma
jRCT2031220739Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Dec 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of isatuximab, carfilzomib and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Sanofi. Primary endpoint: Overall response rate. Started Dec 2023; status: active, not recruiting.
02
Drugs
isatuximabcarfilzomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2031220739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220739.